This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/pubchem-compound/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/drugbank/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01342/identifier/chemspider/

Statements

Subject Item
n2:DB01342
rdf:type
n5:Drug
n5:description
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
n5:group
approved
n5:indication
For the treatment of hypertension.
owl:sameAs
n8:DB01342 n11:DB01342
dcterms:title
Forasartan
adms:identifier
n4:PA164776845 n10:46505698 n12:DB01342 n13:132706 n14:50049209 n15:117146
n5:mechanismOfAction
Forasartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. Also, since angiotensin causes vasoconstriction, the inhibition of this receptor decreases vasoconstriction, which consequently also decreases vascular resistnace.
n5:synonym
Forasartan SC-52458
n5:IUPAC-Name
n6:271B4073-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4079-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4078-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4075-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4076-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4077-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4071-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B406F-363D-11E5-9242-09173F13E4C5 n6:271B4072-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4070-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B407F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4080-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B407A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B407B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B407D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B407C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B407E-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
145216-43-9
n5:category
n5:Bioavailability
n6:271B4085-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4087-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4088-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4084-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4083-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4086-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4074-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4081-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4082-363D-11E5-9242-09173F13E4C5